The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
Authors
Keywords
-
Journal
NATURAL PRODUCT REPORTS
Volume 30, Issue 5, Pages 625
Publisher
Royal Society of Chemistry (RSC)
Online
2013-03-25
DOI
10.1039/c3np20113a
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Status of Anti-Cancer Agents Derived from Marine Sources
- (2013) Ram Singh et al. Anti-Cancer Agents in Medicinal Chemistry
- Merging Chemical Synthesis and Biosynthesis: A New Chapter in the Total Synthesis of Natural Products and Natural Product Libraries
- (2012) Andreas Kirschning et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Advances in bispecific biotherapeutics for the treatment of cancer
- (2012) Chad May et al. BIOCHEMICAL PHARMACOLOGY
- Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
- (2012) R Y Tsang et al. BRITISH JOURNAL OF CANCER
- A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer
- (2012) Muralidhar Beeram et al. CANCER
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Targeting Cancer Stem Cells with Natural Products
- (2012) Joseph Burnett et al. CURRENT DRUG TARGETS
- Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?
- (2012) David M. Pereira et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
- (2012) Christos D. Katsetos et al. CURRENT PHARMACEUTICAL DESIGN
- Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia
- (2012) Xavier Thomas EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mitochondria and cell signalling
- (2012) Stephen W. G. Tait et al. JOURNAL OF CELL SCIENCE
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
- (2012) H. K. Erickson et al. MOLECULAR CANCER THERAPEUTICS
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- PI3K signalling: the path to discovery and understanding
- (2012) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Pharmacokinetic Considerations for Antibody Drug Conjugates
- (2012) Kedan Lin et al. PHARMACEUTICAL RESEARCH
- Mitochondrial Fission, Fusion, and Stress
- (2012) R. J. Youle et al. SCIENCE
- Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling
- (2012) Christian Appenzeller-Herzog et al. TRENDS IN CELL BIOLOGY
- Biosynthetic medicinal chemistry of natural product drugs
- (2012) Frank E. Koehn MedChemComm
- PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
- (2012) Lise Willems et al. Current Oncology Reports
- Defective Regulation of Autophagy upon Leucine Deprivation Reveals a Targetable Liability of Human Melanoma Cells In Vitro and In Vivo
- (2011) Joon-Ho Sheen et al. CANCER CELL
- Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells
- (2011) M. Damelin et al. CANCER RESEARCH
- Prohibitin(g) Cancer: Aurilide and Killing by Opa1-Dependent Cristae Remodeling
- (2011) Martina Semenzato et al. CHEMISTRY & BIOLOGY
- Structural and conformational features relevant to the anti-tumor activity of calicheamicin γ 1I
- (2011) George A. Ellestad CHIRALITY
- Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
- (2011) T. M. Cardillo et al. CLINICAL CANCER RESEARCH
- SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
- (2011) V. Blanc et al. CLINICAL CANCER RESEARCH
- A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
- (2011) M. A. Fanale et al. CLINICAL CANCER RESEARCH
- Introduction to current and future protein therapeutics: A protein engineering perspective
- (2011) Paul J. Carter EXPERIMENTAL CELL RESEARCH
- Brentuximab Vedotin (SGN-35), an antibody–drug conjugate for the treatment of CD30-positive malignancies
- (2011) Antonio Gualberto EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Investigational antibody drug conjugates for solid tumors
- (2011) Puja Sapra et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mitochondria targeting of non-peroxidizable triphenylphosphonium conjugated oleic acid protects mouse embryonic cells against apoptosis: Role of cardiolipin remodeling
- (2011) Yulia Y. Tyurina et al. FEBS LETTERS
- Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
- (2011) Robert Y. Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
- (2011) P. Walter et al. SCIENCE
- Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space
- (2011) Alexander Alex et al. MedChemComm
- Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75
- (2010) M C Ryan et al. BRITISH JOURNAL OF CANCER
- Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
- (2010) Y. V. Kovtun et al. CANCER RESEARCH
- Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
- (2010) J. R. Junutula et al. CLINICAL CANCER RESEARCH
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice
- (2010) Nelson L. Jumbe et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Distinct Biological Network Properties between the Targets of Natural Products and Disease Genes
- (2010) Vlado Dančík et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Complexity and simplicity in the biosynthesis of enediyne natural products
- (2010) Zhao-Xun Liang NATURAL PRODUCT REPORTS
- Antibody–drug conjugates for cancer: poised to deliver?
- (2010) Bethan Hughes NATURE REVIEWS DRUG DISCOVERY
- Targeting mitochondria for cancer therapy
- (2010) Simone Fulda et al. NATURE REVIEWS DRUG DISCOVERY
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates
- (2009) Hans K. Erickson et al. BIOCONJUGATE CHEMISTRY
- Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
- (2009) Laurent Ducry et al. BIOCONJUGATE CHEMISTRY
- Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
- (2009) Piyush B. Gupta et al. CELL
- Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines
- (2009) R. Stein et al. CLINICAL CANCER RESEARCH
- Tubulin-Interactive Natural Products as Anticancer Agents(1)
- (2009) David G. I. Kingston JOURNAL OF NATURAL PRODUCTS
- Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
- (2009) Bin-Bing S. Zhou et al. NATURE REVIEWS DRUG DISCOVERY
- The influence of lead discovery strategies on the properties of drug candidates
- (2009) György M. Keserü et al. NATURE REVIEWS DRUG DISCOVERY
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Determination of the Biological Activity and Structure Activity Relationships of Drugs Based on the Highly Cytotoxic Duocarmycins and CC-1065
- (2009) Lutz Tietze et al. Toxins
- Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
- (2008) Jordi Rodon et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Highly Active Ansamitocin Derivatives: Mutasynthesis Using an AHBA-Blocked Mutant
- (2008) Florian Taft et al. CHEMBIOCHEM
- Marine pharmacology in 2005–2006: Antitumour and cytotoxic compounds
- (2008) Alejandro M.S. Mayer et al. EUROPEAN JOURNAL OF CANCER
- Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
- (2008) Roberto Stasi EXPERT OPINION ON BIOLOGICAL THERAPY
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
- Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities
- (2008) Inki Kim et al. NATURE REVIEWS DRUG DISCOVERY
- Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma
- (2008) Herbert Riechelmann et al. ORAL ONCOLOGY
- Selection of Reaction Additives Used in the Preparation of Monomeric Antibody−Calicheamicin Conjugates
- (2007) Irwin Hollander et al. BIOCONJUGATE CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started